{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:52:34Z","timestamp":1788493954998,"version":"build-2803163510"},"reference-count":51,"publisher":"American Association for Cancer Research (AACR)","issue":"11","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Servier Laboratories | Institut de Recherches Servier"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,30]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>UCART191 is an \u201coff-the-shelf\u201d genome-edited anti-CD19 chimeric antigen receptor (CAR)-T cell product, manufactured from unrelated healthy donor cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>UCART19 was administered to 25 adult patients with relapsed or refractory (R\/R) B-cell acute lymphoblastic leukemia (B-ALL) in the CALM trial. All patients underwent lymphodepletion with fludarabine and cyclophosphamide \u00b1 alemtuzumab and received one of three ascending doses of UCART19. Given the allogeneic nature of UCART19, we analyzed the impact of lymphodepletion, HLA disparities, and host immune system reconstitution on its kinetics, along with other factors known to affect autologous CAR-T cell clinical pharmacology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Responder patients (12\/25) had higher UCART19 expansion (Cmax) and exposure (AUCTlast) than nonresponders (13\/25), as measured by transgene levels in peripheral blood. The persistence of CAR+ T cells did not exceed 28 days in 10\/25 patients and lasted beyond 42 days in 4\/25. No significant correlation was found between UCART19 kinetics and administered cell dose, patient and product characteristics or HLA disparities. However, the number of prior lines of therapy and absence of alemtuzumab negatively impacted UCART19 expansion and persistence. Alemtuzumab exposure positively affected IL7 and UCART19 kinetics, while negatively correlating with host T lymphocyte AUC0-28.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>UCART19 expansion is a driver of response in adult patients with R\/R B-ALL. These results shed light on the factors associated with UCART19 kinetics, which remain highly affected by the impact of alemtuzumab on IL7 and host-versus-graft rejection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>First description of the clinical pharmacology of a genome-edited allogeneic anti-CD19 CAR-T cell product showing the crucial role of an alemtuzumab-based regimen in sustaining UCART19 expansion and persistence through increased IL7 availability and decreased host T lymphocyte population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-22-0175","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T10:48:11Z","timestamp":1667818091000},"page":"1520-1531","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia"],"prefix":"10.1158","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3236-2095","authenticated-orcid":true,"given":"Sandra","family":"Dupouy","sequence":"first","affiliation":[{"name":"1Institut de Recherches Internationales Servier, Suresnes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibtissam","family":"Marchiq","sequence":"additional","affiliation":[{"name":"2Institut de Recherches Servier, Croissy-sur-Seine, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2132-5173","authenticated-orcid":true,"given":"Thibaud","family":"Derippe","sequence":"additional","affiliation":[{"name":"1Institut de Recherches Internationales Servier, Suresnes, France."},{"name":"3Universit\u00e9 Paris-Descartes, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3513-0919","authenticated-orcid":true,"given":"Maria","family":"Almena-Carrasco","sequence":"additional","affiliation":[{"name":"1Institut de Recherches Internationales Servier, Suresnes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Jozwik","sequence":"additional","affiliation":[{"name":"4King's College Hospital NHS Foundation Trust, London, England."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5898-3677","authenticated-orcid":true,"given":"Sylvain","family":"Fouliard","sequence":"additional","affiliation":[{"name":"1Institut de Recherches Internationales Servier, Suresnes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5509-8912","authenticated-orcid":true,"given":"Yasmina","family":"Adimy","sequence":"additional","affiliation":[{"name":"1Institut de Recherches Internationales Servier, Suresnes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Geronimi","sequence":"additional","affiliation":[{"name":"1Institut de Recherches Internationales Servier, Suresnes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Graham","sequence":"additional","affiliation":[{"name":"4King's College Hospital NHS Foundation Trust, London, England."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[{"name":"5The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-0393","authenticated-orcid":true,"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[{"name":"6Massachusetts General Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"name":"7Sorbonne University, Saint-Antoine Hospital, INSERM UMRs 938, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2091-7927","authenticated-orcid":true,"given":"Nicolas","family":"Boissel","sequence":"additional","affiliation":[{"name":"8Saint-Louis Hospital, URP-3518, Institut de Recherche Saint-Louis, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0941-271X","authenticated-orcid":true,"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[{"name":"9Hokkaido University Hospital, Sapporo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuben","family":"Benjamin","sequence":"additional","affiliation":[{"name":"4King's College Hospital NHS Foundation Trust, London, England."},{"name":"11King's College London, London, England."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2094-8451","authenticated-orcid":true,"given":"Svetlana","family":"Balandraud","sequence":"additional","affiliation":[{"name":"1Institut de Recherches Internationales Servier, Suresnes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"103239","DOI":"10.1016\/j.critrevonc.2021.103239","article-title":"Chimeric antigen receptor T cell therapy in oncology - pipeline at a glance: analysis of the ClinicalTrials.gov database","volume":"159","author":"Moreno-Cortes","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet North Am Ed"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/cam4.3686","article-title":"Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed\/refractory large B-cell lymphoma in China","volume":"10","author":"Ying","year":"2021","journal-title":"Cancer Med"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11095-018-2436-z","article-title":"Chimeric antigen receptor T-cells (CAR T-cells) for cancer immunotherapy\u2014moving target for industry?","volume":"35","author":"Salmikangas","year":"2018","journal-title":"Pharm Res"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma","volume":"37","author":"Lin","year":"2019","journal-title":"J Clin Oncol"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","article-title":"A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy","volume":"124","author":"Philip","year":"2014","journal-title":"Blood"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex genome-edited T-cell manufacturing platform for \"Off-the-Shelf\" adoptive T-cell immunotherapies","volume":"75","author":"Poirot","year":"2015","journal-title":"Cancer Res"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","article-title":"UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial","volume":"9","author":"Benjamin","year":"2022","journal-title":"Lancet Haematol"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.omtm.2018.01.010","article-title":"The pharmacology of T cell therapies","volume":"8","author":"Milone","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","article-title":"CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date","volume":"127","author":"Park","year":"2016","journal-title":"Blood"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/blood-2019-03-900928","article-title":"CAR-T efficacy: is conditioning the key?","volume":"133","author":"Neelapu","year":"2019","journal-title":"Blood"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.4049\/jimmunol.0901440","article-title":"Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells","volume":"184","author":"Cheadle","year":"2010","journal-title":"J Immunol"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"e1049","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin Transl Immunology"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"17884","DOI":"10.1038\/s41598-020-74927-8","article-title":"Quantitative PCR methodology with a volume-based unit for the sophisticated cellular kinetic evaluation of chimeric antigen receptor T cells","volume":"10","author":"Yamamoto","year":"2020","journal-title":"Sci Rep"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","article-title":"Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia","volume":"24","author":"Mueller","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ncponc0666","article-title":"Increased intensity lymphodepletion and adoptive immunotherapy\u2013how far can we go?","volume":"3","author":"Muranski","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1182\/blood-2011-10-386482","article-title":"Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer","volume":"119","author":"Yao","year":"2012","journal-title":"Blood"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","article-title":"Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs","volume":"125","author":"Ninomiya","year":"2015","journal-title":"Blood"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1182\/blood.V126.23.4426.4426","article-title":"Cyclophosphamide and fludarabine conditioning chemotherapy induces a key homeostatic cytokine profile in patients prior to CAR T cell therapy","volume":"126","author":"Bot","year":"2015","journal-title":"Blood"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.smim.2007.10.004","article-title":"T cell immune reconstitution following lymphodepletion","volume":"19","author":"Williams","year":"2007","journal-title":"Semin Immunol"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Na\u00efve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers","volume":"9","author":"Das","year":"2019","journal-title":"Cancer Discov"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/sj.bmt.1704861","article-title":"The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants","volume":"35","author":"Gahrton","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.beha.2006.09.007","article-title":"Risk assessment in haematopoietic stem cell transplantation: impact of donor-recipient sex combination in allogeneic transplantation","volume":"20","author":"Gahrton","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1097\/01.ASN.0000030078.74889.69","article-title":"The effect of donor gender on graft survival","volume":"13","author":"Zeier","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1016\/j.transproceed.2010.07.029","article-title":"The impact of H-Y mismatches on results of HLA-matched unrelated allogeneic hematopoietic stem cell transplantation","volume":"42","author":"Markiewicz","year":"2010","journal-title":"Transplant Proc"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/978-1-0716-0146-4_17","article-title":"Analysis of CAR-mediated tonic signaling","volume":"2086","author":"Calderon","year":"2020","journal-title":"Methods Mol Biol"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.celrep.2017.09.015","article-title":"Tonic 4\u20131BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent","volume":"21","author":"Gomes-Silva","year":"2017","journal-title":"Cell Rep"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4\u20131BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40425-018-0385-z","article-title":"CART cells are prone to Fas- and DR5-mediated cell death","volume":"6","author":"Tschumi","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2018-01-828343","article-title":"Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL","volume":"132","author":"Rossi","year":"2018","journal-title":"Blood"},{"key":"2023032313595007600_","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1158\/2767-9764.CRC-22-0176","article-title":"Mechanistic modeling of the interplay between host immune system, interleukin 7 and UCART19 allogeneic CAR-T cells in adult B-cell acute lymphoblastic leukemia","volume":"2","author":"Derippe","year":"2022","journal-title":"Cancer Research Communications"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-22-0175\/3221645\/crc-22-0175.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/11\/1520\/3285003\/crc-22-0175.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/11\/1520\/3285003\/crc-22-0175.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T05:34:23Z","timestamp":1701322463000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/2\/11\/1520\/711326\/Clinical-Pharmacology-and-Determinants-of-Response"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,30]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0175","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.22546538","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546535.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546535","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6551198","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546532.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6551198.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546532","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546538.v1","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]}}}